GHIC’s Catalytic Health Investment Platform and BlueMark Announce Partnership to Strengthen Impact Capabilities of Fund Managers Accelerating Healthcare Innovation in Low- and Middle-Income Countries.

New York, NY / November 20, 2025

The Global Health Investment Corporation (GHIC), through its Catalytic Health Investment Platform (CHIP), and BlueMark, a leading provider of independent impact assessments and market intelligence for the investment industry, today announced a strategic partnership to strengthen impact practices and performance of fund managers investing in healthcare innovation for underserved populations in low- and middle-income countries (LMICs). The partnership will be supported by funding from a CHIP grant.

CHIP is a 20-year partnership between GHIC and the German Government, through its Federal Ministry for Economic Cooperation and Development (BMZ) and Public Development Bank KfW, to accelerate the development of public health technologies and products to improve global health. A central component of the platform is catalysis of healthcare impact through CHIP investments in funds with a clear mission to improve health outcomes in LMICs. BlueMark has extensive experience evaluating and verifying impact practices and performance, including detailed assessments for over 330 investment strategies representing nearly half a trillion dollars worth of investments. Through this partnership, CHIP will customize and deploy BlueMark's state-of-the-art impact platform, including its fund verification process (“Fund ID”), portfolio analytics and market intelligence. This will enable rigorous impact assessment and monitoring of CHIP investments, and empower the ecosystem of global health fund managers in expanding their impact capabilities through access to BlueMark’s suite of tools and insights.

"As more fund managers look to opportunities in the healthcare sector, it is imperative that the investors in these funds have a reliable way to assess and track the impact of their investments," said Christina Leijonhufvud, CEO of BlueMark. "Through this partnership with GHIC's Catalytic Health Investment Platform, we are committed to delivering valuable data and insights that can unlock more capital for the global health impact investment ecosystem."

“Core to CHIP’s mission is maximizing the impact of investments in healthcare innovation for underserved populations,” said Julian Peat, Head, Catalytic Health Investment Platform, GHIC. “Partnering with BlueMark is a compelling opportunity to enhance CHIP’s diligence and management practices, and make available an industry-leading impact platform to the global health investment ecosystem. We look forward to supporting the growth of mission-aligned fund managers as they deepen their contributions to improved health for all.”

“We are grateful to our partners at GHIC's Catalytic Health Investment Platform for enabling us to undertake the Fund ID process with BlueMark,” said Carl Nicholas Ng, General Partner & Head of Impact, Verge HealthTech Fund- a CHIP portfolio fund. “We found it invaluable to benchmark our existing impact commitments and practices, as well as identifying how we can continue to evolve and grow as an impact investment firm. The feedback provided by BlueMark reinforces Verge's commitment to investing in globally relevant, impactful healthtech startups.”

This collaboration underscores a shared commitment to advancing the impact investing ecosystem, with a focus on mobilizing transformative investment into the vital field of global health. By joining forces, BlueMark and CHIP are connecting leading impact practices with real-world innovation to drive healthcare impact for underserved populations in LMICs.

To learn more about the partnership and ongoing initiatives, please visit www.bluemark.co or www.ghicfunds.org.

About GHIC and the Catalytic Health Investment Platform (CHIP):

GHIC, a nonprofit organization, has been investing in global health innovation for over a decade. GHIC seeks to catalyze the development of technologies to improve global health through investments in vaccines, therapeutics, diagnostics, medical devices, and other technologies to save and improve lives, by mobilizing private, public, and philanthropic capital via innovative partnership models. GHIC leverages the engagement, networks, and funding of its strategic partners and stakeholders to drive innovation, and invest in innovative health technologies for a healthier, safer world.

The Catalytic Heath Investment Platform (CHIP) is a twenty-year partnership between GHIC and the Government of Germany, through its Federal Ministry for Economic Cooperation and Development (BMZ) and KfW, to accelerate the development of public health technologies and products to improve global health. CHIP catalyzes health innovations to address the needs of underserved populations in low- and middle-income countries through investments in funds and companies as well as grant making opportunities.

For more information about GHIC, please visit www.ghicfunds.org. Inquiries regarding the Catalytic Health Investment Platform can be directed to CHIP@ghicfunds.org.

About BlueMark

BlueMark is a leading provider of independent impact assessments and market intelligence for the investment industry. As a certified B Corp, BlueMark’s mission is to strengthen trust and transparency in impact data by equipping investors with the tools, insights, and analytics needed to better monitor and evaluate their investment portfolios. BlueMark has completed hundreds of impact assessments for diverse investors globally. Building off that expertise, the BlueMark IQ platform is custom-designed for asset allocators to more easily identify, monitor, and report on fund and portfolio-level impact. Learn more at www.bluemark.co.